Overview

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Status:
Completed
Trial end date:
2018-04-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare lenalidomide to a control drug and see which one delays Diffuse Large B-Cell Lymphoma (DLBCL) disease progression longer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Etoposide
Etoposide phosphate
Gemcitabine
Lenalidomide
Oxaliplatin
Rituximab
Thalidomide